These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21335510)

  • 1. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study.
    Bourke L; Doll H; Crank H; Daley A; Rosario D; Saxton JM
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):647-57. PubMed ID: 21335510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer.
    Ott C; Fulton MK
    J Am Acad Nurse Pract; 2005 Mar; 17(3):113-22. PubMed ID: 15748224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
    Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
    J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
    Galvão DA; Taaffe DR; Spry N; Newton RU
    Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
    Hayes JH; Chen MH; Moran BJ; Braccioforte MH; Dosoretz DE; Salenius S; Katin MJ; Ross R; Choueiri TK; D'Amico AV
    BJU Int; 2010 Oct; 106(7):979-85. PubMed ID: 20230380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.
    Hansen PA; Dechet CB; Porucznik CA; LaStayo PC
    PM R; 2009 Nov; 1(11):1019-24. PubMed ID: 19942188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nursing implications of androgen deprivation therapy-associated bone loss.
    Weingard KK
    Urol Nurs; 2006 Aug; 26(4):261-9; quiz 270. PubMed ID: 16939043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    J Clin Oncol; 2010 Jan; 28(2):340-7. PubMed ID: 19949016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A qualitative study evaluating experiences of a lifestyle intervention in men with prostate cancer undergoing androgen suppression therapy.
    Bourke L; Sohanpal R; Nanton V; Crank H; Rosario DJ; Saxton JM
    Trials; 2012 Nov; 13():208. PubMed ID: 23151126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of androgen suppression in the treatment of prostate cancer.
    Bolla M; de Reijke TM; Van Tienhoven G; Van den Bergh AC; Oddens J; Poortmans PM; Gez E; Kil P; Akdas A; Soete G; Kariakine O; van der Steen-Banasik EM; Musat E; Piérart M; Mauer ME; Collette L;
    N Engl J Med; 2009 Jun; 360(24):2516-27. PubMed ID: 19516032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
    J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality.
    D'Amico AV; McLeod DG; Carroll PR; Cullen J; Chen MH
    Cancer; 2007 Apr; 109(7):1290-5. PubMed ID: 17315162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure.
    Bolam KA; Galvão DA; Spry N; Newton RU; Taaffe DR
    Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):329-38. PubMed ID: 22733158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Androgen suppression for the treatment of prostate cancer in the elderly].
    Mongiat-Artus P; Peyromaure M; Richaud P; Beuzeboc P; Bastide C; Cornud F; Gaschignard N; Molinié V; Rozet F; Staerman F; Soulié M; Salomon L;
    Prog Urol; 2009 Nov; 19 Suppl 3():S151-5. PubMed ID: 20123501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA
    J Urol; 2007 Jan; 177(1):17-24. PubMed ID: 17161994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.